News

Ideas That Generate Results

According to a new report by RNCOS, the US Cancer Vaccines Market, though still in infancy, is experiencing a favorable environment due to the immense therapeutic potential it holds. Both, the government and private players are actively funding projects aimed at exploring new candidate cancer vaccines.

Besides, prophylactic cancer vaccine makers Merck and GSK are being favored and promoted by the government for their vaccine's ability to prevent cervical cancer, a leading cause of mortality due to cancer in females. The study reveals that no new player is expected to hit the US market for prophylactic vaccines in another five years at least, making it a lucrative segment for Merck and GSK. Moreover, both the companies are conducting various clinical trials to further strengthen their vaccine's coverage and increase their customer base. The market is anticipated to grow at a 1.4% CAGR to become US$ 2.76 Billion.

Research Analysis & Highlights

The report entitled "US Cancer Vaccine Market Outlook 2020", provides an effective analysis of the market drivers, current market size and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Moreover, an in-depth analysis of all the candidate cancer vaccines in various phases of clinical trials for most prevalent cancers in US has been done to identify diverse opportunities for players.

Further, the report provides competitive analysis of the promising players in the market along with their key strategies for business expansion. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines to the industry for clinical proceedings of cancer therapeutic vaccines has also been provided.

Some of the report's key highlights include:

          - Promising therapeutic cancer vaccines in phase-3 clinical trials to influence market
          dynamics
          - Introduction of vaccines for EBV, HTLV-1, H. pylori can help reduce cancer
          burden
          - Significant potential underlines the therapeutics cancer vaccines
          - Leading Players and their share in US cancer vaccine Market

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM772.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm